Loading...
 
Toggle Health Problems and D

4X less of one chemo needed after vitamin D receptor activation - June 2020

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy

Molecular Cancer Theraputics DOI: 10.1158/1535-7163.MCT-19-0791
Sriram Anbil, Michael Pigula, Huang-Chiao Huang, Srivalleesha Mallidi, Mans Broekgaarden, Yan Baglo, Pushpamali De Silva, Diane M. Simeone, Mari Mino-Kenudson, Edward V. Maytin, Imran Rizvi and Tayyaba Hasan

VitaminDWiki

Cancer - After diagnosis has the following chart

see wikipage: http://www.vitamindwiki.com/tiki-index.php?page_id=396
         click on chart for details


Items in both categories Cancer - After diagnosis and Vitamin D Receptor:


Vitamin D Receptor and Cancers

Items in both categories Vitamin D Receptor and Cancer - Breast:

Items in both categories Vitamin D Receptor and Cancer - Colon:

Items in both categories Vitamin D Receptor and Cancer

Items in both categories Vitamin D Receptor and Cancer - other:

Items in both categories Vitamin D Receptor and Cancer - Skin:

Items in both categories Vitamin D Receptor and Cancer - Prostate:

Items in both categories Vitamin D Receptor and Cancer - Ovarian:

 Download the PDF from Sci-Hub iva VitaminDWiki
Image

Patients with cancer often confront the decision of whether to continue high-dose chemotherapy at the expense of cumulative toxicities. Reducing the dose of chemotherapy regimens while preserving efficacy is sorely needed to preserve the performance status of these vulnerable patients, yet has not been prioritized. Here, we introduce a dual pronged approach to modulate the microenvironment of desmoplastic pancreatic tumors and enable significant dose deescalation of the FDA-approved chemotherapeutic nanoliposomal irinotecan (nal-IRI) without compromising tumor control. We demonstrate that light-based photodynamic priming (PDP) coupled with vitamin D3 receptor (VDR) activation within fibroblasts increases intratumoral nal-IRI accumulation and suppresses protumorigenic CXCL12/CXCR7 crosstalk. Combined photodynamic and biochemical modulation of the tumor microenvironment enables a 75% dose reduction of nal-IRI while maintaining treatment efficacy, resulting in improved tolerability. Modifying the disease landscape to increase the susceptibility of cancer, via preferentially modulating fibroblasts, represents a promising and relatively underexplored strategy to enable dose deescalation. The approach presented here, using a combination of three clinically available therapies with nonoverlapping toxicities, can be rapidly translated with minimal modification to treatment workflow, and challenges the notion that significant improvements in chemotherapy efficacy can only be achieved at the expense of increased toxicity.


Created by admin. Last Modification: Saturday May 1, 2021 01:55:43 GMT-0000 by admin. (Version 4)

Attached files

ID Name Comment Uploaded Size Downloads
13875 Chemo VDR.jpg admin 02 Jun, 2020 19:13 115.69 Kb 196
13874 Chemo reduced 4X by activation of VDR sci-hub_compressed.pdf PDF 2020 admin 02 Jun, 2020 19:12 1.17 Mb 151
See any problem with this page? Report it (FINALLY WORKS)